Your Gut Bacteria May Talk to Your Immune System Before Multiple Sclerosis Strikes

A large genetic study has uncovered tentative evidence that specific gut bacteria could influence the risk of multiple sclerosis (MS) through the activation of particular immune cells, offering a fresh — though still highly preliminary — glimpse into the hidden communication channels that may connect the microbes living in our intestines with the destruction of myelin in the brain and spinal cord.

The new research, published in the journal Immunity, Inflammation and Disease, used a sophisticated statistical technique known as Mendelian randomization (MR) to probe whether the gut microbiota might exert causal effects on MS risk, and whether immune cell traits stand in the middle of that relationship. The team, led by Pingping Ning and Rui Li, drew on genetic data from tens of thousands of people to build what they describe as an exploratory “gut microbiota–immune traits–MS axis.” Their headline finding: two well-known gut bacterial genera, Roseburia and Ruminococcus2, appear to influence MS risk at least partly by modulating markers on the surface of CD4+ and CD8+ T cells — the very soldiers of the adaptive immune system that are widely suspected of turning against the nervous system in people with MS.

Multiple sclerosis is one of the most common causes of non-traumatic disability in young adults, affecting an estimated 2.8 million people worldwide. The disease is characterized by the immune system’s assault on the myelin sheaths that insulate nerve fibers in the central nervous system, producing symptoms ranging from motor weakness and sensory loss to vision impairment and cognitive decline. Its incidence has climbed sharply in recent years — with roughly 500,000 new cases added globally since 2013 — and women are about three times more likely than men to be diagnosed. The annual economic burden of MS in the United States alone is estimated at $85.4 billion. Yet despite decades of research, the precise triggers of the disease remain stubbornly unclear, with evidence pointing to an intricate interplay between genetics, environmental exposures, and lifestyle factors.

That is where the gut microbiome enters the picture. The intestine is far more than a digestive organ; it is a major hub of immune regulation, and the trillions of microbes it harbors are known to shape immune function in profound ways. When the microbial community becomes imbalanced — a state known as dysbiosis — the production of microbial metabolites can shift, altering the behavior of antigen-presenting cells, T cells, and B cells. This, in turn, may set the stage for autoimmune diseases. Previous studies have found altered gut bacterial composition and reduced levels of short-chain fatty acids in people with MS, but whether these microbial changes actually cause the disease — and through what biological intermediaries — has remained an open question.

Mendelian randomization offered the researchers a way to address that question with observational data. The technique exploits the random allocation of genetic variants at conception as a natural experiment: because single nucleotide polymorphisms (SNPs) are inherited randomly and are fixed at conception, they are largely immune to the confounding and reverse-causation biases that plague traditional observational studies. In essence, MR uses genetic variants as proxies — instrumental variables — to ask whether an exposure genuinely influences an outcome, in a manner loosely analogous to a randomized controlled trial.

The data underpinning the study were formidable. For gut microbiota, the team used summary statistics from the MiBioGen consortium, covering 18,340 participants from 24 cohorts, most of European ancestry, spanning 211 microbial taxa across phyla, classes, orders, families, and genera. For immune traits, they turned to a dataset of 731 immune cell phenotypes measured by flow cytometry in 3,757 individuals from a Sardinian founder population — a rich catalog capturing absolute cell counts, surface antigen expression levels, morphological parameters, and ratios between cell populations. For MS outcomes, they accessed genome-wide association data from the International Multiple Sclerosis Genetics Consortium comprising 47,429 MS cases and 68,374 controls of European ancestry.

The analysis proceeded in stages. First, the researchers screened all 211 microbial taxa for genetic associations with MS and identified six taxa with nominally significant associations — four apparently protective, two apparently risk-increasing. Notably, the genus Ruminiclostridium5 showed the strongest nominal protective signal (odds ratio 0.695, 95% confidence interval 0.554–0.871; p = 0.0016). Next, they tested the 731 immune traits for causal links to MS, finding 52 with nominal associations. Finally, they searched for the crucial middle links: microbial taxa and immune traits that formed a statistically coherent triangle, in which the microbe was associated with both the immune trait and MS, and the immune trait was associated with MS, with effect directions consistent with a genuine mediation pathway.

Only two such pathways survived this filtering. The genus Roseburia appeared to influence MS through the expression of CD28 on CD28+ CD4+ T cells, with an estimated 8.97% of the taxon’s nominal effect on MS mediated through this immune trait. The genus Ruminococcus2 appeared to act through CD45 expression on HLA-DR+ CD8+ T cells, mediating an estimated 12.18% of its nominal effect. Both mediation effects had confidence intervals that did not cross zero, lending them a degree of statistical credibility despite the overall exploratory nature of the analysis.

The mechanistic story behind these findings is biologically plausible. Both Roseburia and Ruminococcus2 are short-chain fatty acid (SCFA)-producing bacteria — fermenters of dietary fiber that generate acetate, propionate, and butyrate. SCFAs nourish colonic epithelial cells and regulate inflammatory responses throughout the body, and they play a key role in gut-brain communication. In MS patients, gut bacterial composition and SCFA levels are often reduced, which is thought to impair regulatory T cell function. Intriguingly, oral propionate supplementation has been shown to increase propionate availability in cerebrospinal fluid and improve clinical outcomes in MS patients, while butyrate ester treatment in mouse models of MS alleviated symptoms, reduced pro-inflammatory Th1 and Th17 cells, and boosted regulatory T cell proportions and IL-10 secretion.

The immune mediators identified in the study are equally compelling. CD28 is a co-stimulatory receptor on T cells that binds CD80 and CD86 on antigen-presenting cells, amplifying T cell activation when the T cell receptor recognizes an antigen. In MS patients, CD28+ CD4+ T cell activation is typically enhanced, and over-activated CD28+ T cells secrete interferon-γ and tumor necrosis factor-α, recruit B cells and macrophages, and contribute to the demyelination process. Excessive CD28 signaling may drive T cells to mount responses against neuroantigens, making CD28-targeting inhibitors a potential future therapeutic strategy. On the CD8+ side, HLA-DR expression marks activated cytotoxic T cells, and HLA-DR+ CD8+ T cells have been implicated in myelin destruction and neurodegeneration — they can recognize central nervous system antigens, exert cytotoxic effects, and release pro-inflammatory cytokines that worsen neuronal damage. CD45, meanwhile, is a tyrosine phosphatase that fine-tunes T cell receptor signaling, making its expression level a meaningful indicator of T cell responsiveness.

The authors are emphatic that these results must be interpreted with caution. All associations reported in the study were nominally significant only — with uncorrected p-values below 0.05 — and none survived false discovery rate (FDR) correction. In other words, the findings are hypothesis-generating clues, not proven causal relationships. The team itself attributes this partly to the low heritability of gut microbial taxa, which limits the statistical power of MR analyses of the microbiome, and to the fact that gut microbiota are heavily shaped by diet and environment, factors that genetic data alone cannot fully capture.

Several other limitations temper the conclusions. The immune trait data came from a Sardinian founder population, which may not represent immune trait distributions elsewhere in the world. The researchers did not perform MR-PRESSO outlier detection due to the computational burden of 58 exposure factors, and reverse MR analysis was not possible because no valid instrumental variables existed for MS as an exposure — meaning reverse causality cannot be ruled out. Multivariable MR and genetic colocalization analyses, which could help disentangle confounding and verify shared genetic signals, were likewise beyond the scope of the study and are flagged as priorities for future well-powered investigations.

Still, the study represents a meaningful step toward mapping the causal architecture of the microbiota-immune-disease axis in MS. By combining two-stage MR with formal mediation analysis, the researchers constructed a coherent, testable framework: fiber-fermenting gut bacteria produce SCFAs, which modulate the activation state of CD4+ and CD8+ T cells, which in turn influence the risk and progression of multiple sclerosis. If confirmed in independent populations and validated in laboratory experiments, this framework could point toward novel biomarkers for predicting disease progression — and toward microbiome-targeted or immune-cell-targeted therapies that intervene early in the disease process. For now, the message from this study is one of cautious optimism: the gut may indeed be whispering to the immune system about MS, and scientists are finally beginning to hear what it says.